0001551152 false Common Stock, $0.01 Par Value ABBV 0001551152 2021-01-12 2021-01-12 0001551152 us-gaap:CommonStockMember exch:XNYS 2021-01-12 2021-01-12 0001551152 exch:XCHI us-gaap:CommonStockMember 2021-01-12 2021-01-12 0001551152 abbv:SeniorNotes0.500Percentdue2021Member exch:XNYS 2021-01-12 2021-01-12 0001551152 abbv:SeniorNotes1.500Percentdue2023Member exch:XNYS 2021-01-12 2021-01-12 0001551152 abbv:SeniorNotes1.375Percentdue2024Member exch:XNYS 2021-01-12 2021-01-12 0001551152 abbv:SeniorNotes1.250Percentdue2024Member exch:XNYS 2021-01-12 2021-01-12 0001551152 abbv:SeniorNotes0.750Percentdue2027Member exch:XNYS 2021-01-12 2021-01-12 0001551152 abbv:SeniorNotes2.125Percentdue2028Member exch:XNYS 2021-01-12 2021-01-12 0001551152 abbv:SeniorNotes2.625Percentdue2028Member exch:XNYS 2021-01-12 2021-01-12 0001551152 abbv:SeniorNotes2.125Percentdue2029Member exch:XNYS 2021-01-12 2021-01-12 0001551152 abbv:SeniorNotes1.250Percentdue2031Member exch:XNYS 2021-01-12 2021-01-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): January 12, 2021

 

ABBVIE INC. 

(Exact Name of Registrant as Specified in its Charter)

_______________________________________________

 

Delaware   001-35565   32-0375147
(State or other Jurisdiction
of Incorporation)
  (Commission File Number)   (IRS Employer
Identification No.)

_______________________________________________

 

1 North Waukegan Road

North Chicago, Illinois 60064-6400

(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: (847) 932-7900

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which
registered
Common Stock, $0.01 Par Value   ABBV   New York Stock Exchange
Chicago Stock Exchange
0.500% Senior Notes due 2021   ABBV21C   New York Stock Exchange
1.500% Senior Notes due 2023   ABBV23B   New York Stock Exchange
1.375% Senior Notes due 2024   ABBV24   New York Stock Exchange
1.250% Senior Notes due 2024   ABBV24B   New York Stock Exchange
0.750% Senior Notes due 2027   ABBV27   New York Stock Exchange
2.125% Senior Notes due 2028   ABBV28   New York Stock Exchange
2.625% Senior Notes due 2028   ABBV28B   New York Stock Exchange
2.125% Senior Notes due 2029   ABBV29   New York Stock Exchange
1.250% Senior Notes due 2031   ABBV31   New York Stock Exchange

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

Item 7.01 Regulation FD Disclosure.

 

On January 12, 2021, AbbVie Inc. posted an investor presentation to its website at: https://investors.abbvie.com/presentations.  A copy is attached as Exhibit 99.1 to this Current Report on Form 8-K.

 

As provided in General Instruction B.2 of Form 8-K, the information in this Item 7.01 and Exhibit 99.1 incorporated herein shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall they be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing. Additionally, the submission of the information set forth in this Item 7.01 is not deemed an admission as to the materiality of any information in this Current Report on Form 8-K that is required to be disclosed solely by Regulation FD.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit
No.
  Exhibit
99.1   Investor Presentation dated January 12, 2021.
104   The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).

 

  2  

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  ABBVIE INC.
   
Date: January 12, 2021 By: /s/ Robert A. Michael
  Name: Robert A. Michael
  Title: Executive Vice President, Chief Financial Officer

 

3 

 

Common Stock, $0.01 Par Value ABBV